Which Anti-amyloid Antibodies are available?

This directory covers 3: Leqembi, Kisunla, Aduhelm.

Anti-Amyloid Antibodies (Alzheimer's)

Also called amyloid-targeting antibodies, Alzheimer's disease-modifying therapy

These are the first medicines that alter the biology of Alzheimer's disease rather than just easing symptoms. Each is an antibody that binds amyloid-beta, the protein that accumulates into plaques in the brain, and clears it. They modestly slow cognitive decline in early disease — and they carry a real risk of ARIA, brain swelling and micro-bleeds that requires MRI monitoring. Their approval has been among the most contested in modern regulatory history.

What this class is used for

Early Alzheimer's disease (mild cognitive impairment and mild dementia)

3 Anti-amyloid Antibodies in this directory

Leqembi

Lecanemab

An antibody that clears amyloid plaques in early Alzheimer's disease.

Kisunla

Donanemab

An intravenous biological therapy used to treat early symptomatic Alzheimer's disease by clearing brain plaque.

Aduhelm

Aducanumab

An early anti-amyloid Alzheimer's therapy.

Compare Anti-amyloid Antibodies side by side

Leqembi VS Kisunla Leqembi VS Aduhelm Kisunla VS Aduhelm

Browse other drug classes

ARBs Antibiotics Antibody-drug Conjugates Anticoagulants Anticonvulsants Antihistamines Antiplatelets Asthma & COPD Inhalers Atypical Antipsychotics BTK Inhibitors Beta Blockers CD20 Antibodies CDK4/6 Inhibitors CGRP Inhibitors COVID-19 Antivirals Checkpoint Inhibitors Cholinesterase Inhibitors Complement Inhibitors DPP-4 Inhibitors EGFR Inhibitors Enzyme Replacement Therapy GLP-1 Agonists Gene & Cell Therapies HIV Antiretrovirals Hepatitis C Antivirals IL-1 Inhibitors IL-17 Inhibitors IL-23 Inhibitors IL-5 Inhibitors IL-6 Inhibitors Insulins JAK Inhibitors PARP Inhibitors PCSK9 Inhibitors Proton Pump Inhibitors SGLT2 Inhibitors SSRIs & SNRIs Statins TNF Inhibitors TTR Silencers Tyrosine Kinase Inhibitors

Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons